COMPANY
Moderna Inc.NAME
mRNA-1273PROGRESS
Phase 3Moderna's mRNA-1273 uses messenger RNA to prompt the body to make a key protein from the virus, creating an immune response.
LATEST NEWS
A preliminary analysis of data from more than 30,000 volunteers showed the shot prevented virtually all symptomatic cases of Covid-19, and also appeared to be effective in preventing the most serious infections. Moderna expects an emergency authorization to be based on a final analysis containing 151 cases, along with two months of safety follow-up data. The program is backed by $955 million from the U.S. government, which separately reached a $1.5 billion deal for 100 million doses.
No comments:
Post a Comment